Dr. Song’s primary research interest is to develop novel and more effective vaccines and immunotherapies for cancers and infectious diseases. Dr. Song’s recent research has been focused on developing i) novel CAR-T/NK therapy for cancers via metabolic reprogramming; ii) neutralization escape variants of oncolytic virus suitable for systemic therapy; and iii) low immunogenic viral vector-based vaccines for infectious diseases such as coronavirus and HIV-1. These novel vaccines and immunotherapies will be evaluated ex vivo using state of the art immunological assays and in vivo using mouse models available in our laboratory. Importantly, the early translational study aims to develop a lead product which could be further evaluated in Phase I clinical trials and if successful, it has a great potential to be fully commercialized.
